MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.830
+0.140
+3.79%
Opening 10:25 06/21 EDT
OPEN
3.750
PREV CLOSE
3.690
HIGH
3.950
LOW
3.730
VOLUME
4.76M
TURNOVER
--
52 WEEK HIGH
3.950
52 WEEK LOW
0.7800
MARKET CAP
518.87M
P/E (TTM)
-10.0288
1D
5D
1M
3M
1Y
5Y
Thinking about buying stock in Citius Pharmaceuticals, New Oriental Education, Cellect Biotechnology, Novan, or Seanergy Maritime?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, EDU, APOP, NOVN, and SHIP.
PR Newswire - PRF · 3d ago
Top 3 Penny Stocks to Buy Right Now for Your 2021 Summer Watchlist
Best Penny Stocks to Watch in Summer 2021
Benzinga · 4d ago
Thinking about buying stock in ContextLogic, Senseonics, BlackBerry, Seanergy Maritime, or Citius Pharmaceuticals?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, SENS, BB, SHIP, and CTXR.
PR Newswire - PRF · 4d ago
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15)
Benzinga · 5d ago
We're Hopeful That Citius Pharmaceuticals (NASDAQ:CTXR) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 5d ago
Citius Pharma Adds Member to Scientific Advisory Board, Shares Touch 52-Week High
marketwatch.com · 5d ago
Citius Pharmaceuticals See Volume; Traders Circulate Seeking Alpha Report 'Citius: Halt For Superiority On The Horizon' With $10 Price Target
https://seekingalpha.com/article/4434912-citius-halt-for-superiority-on-the-horizon
Benzinga · 5d ago
Stocks That Hit 52-Week Highs On Tuesday
    Before 10 a.m. ET on Tuesday, 125 stocks hit new 52-week highs.
Benzinga · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTXR. Analyze the recent business situations of Citius Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTXR stock price target is 6.00 with a high estimate of 8.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 47
Institutional Holdings: 11.20M
% Owned: 8.27%
Shares Outstanding: 135.47M
TypeInstitutionsShares
Increased
12
6.36M
New
21
2.97M
Decreased
1
13.90K
Sold Out
4
198.22K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.71%
Pharmaceuticals & Medical Research
+0.34%
Key Executives
Chairman/Executive Director/Secretary
Leonard Mazur
President/Chief Executive Officer/Director
Myron Holubiak
Chief Financial Officer
Jaime Bartushak
Vice President/Director of Investor Relations
Ilanit Allen
Independent Director
Suren Dutia
Independent Director
Eugene Holuka
Independent Director
William Kane
Independent Director
Howard Safir
Independent Director
Carol Webb
No Data
  • All
  • Financials
  • Insiders
More
About CTXR
Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is focused on developing and commercializing care products with a focus on anti-infective products in adjunct cancer care and prescription products. It has three product candidates: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). Mino-Lok product is designed to salvage the central venous catheters CVC, obviating the need to remove and replace the catheter. Mino-Wrap is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. CITI-002 is being developed for symptomatic relief of hemorrhoids. CITI-002 combines the steroid, halobetasol, with lidocaine.

Webull offers kinds of Citius Pharmaceuticals Inc stock information, including NASDAQ:CTXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTXR stock methods without spending real money on the virtual paper trading platform.